Compare CytoLynx Therapeutics vs Fate Therapeutics
Customers evaluate the quality of CytoLynx Therapeutics's products using the following success metrics.
Overview
CytoLynx Therapeutics is 3 yrs old and is based in China.
CytoLynx, a joint venture created by Cytovia and TF Capital and supported by other leading investors, s a China-based R&D and commercial platform leveraging Cytovia’s unique technologies and product pipeline. It aims to bring disruptive medicines to Greater China and world-wide.
Fate Therapeutics is 17 yrs old and is based in United States.
Fate Therapeutics (NASDAQ: FATE) is a biotechnology company developing stem cell modulators (SCMs), biologic or small molecule compounds that guide cell fate, to treat patients with very few therapeutic options. Fate Therapeutics' lead clinical program, ProHema, consists of pharmacologicallyenhanced hematopoietic stem cells (HSCs) designed to improve HSC support during the normal course of a stem cell transplant for the treatment of patients with hematologic malignancies. The Company is also advancing a pipeline of human recombinant proteins, each with mechanisms of action, for skeletal muscle, beta-Aislet cell, and post-Aischemic tissue regeneration. Fate Therapeutics also applies its induced pluripotent stem cell (iPSC) technology to offer a highly efficient platform to recapitulate human physiology for commercial scale drug discovery and therapeutic use.
Demo Video
Funding
Investors
Yunfeng Capital, Tigermed
Polaris Partners, ARCH Venture Partners
Product
Why CytoLynx Therapeutics beats Fate Therapeutics
- indications
Information not available because Fate Therapeutics has not claimed their profile.
Work for Fate Therapeutics? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Fate Therapeutics?
Claim your profile now.
Benefits
Products
CYT-100
iPSC-NK cells to improve immune system and cure cancer.
Customers
Known Partners
Why They Buy